Immunohistochemical expressions of p16 and p53 proteins in cervical intraepithelial neoplasia and in benign cervical tissue

European Journal of Gynaecological Oncology

Volumn 31, Issue 6, 2010, Pages 627-631

  Tosun, G ^a   Sendag, F ^a   Zeybek, B ^a   Cosan Terek, M ^a   Guven, C ^a   Zekiogly, O ^a   Bilgin, O ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Chronic cervicitis; CIN; P16; P53

Indexed keywords

PROTEIN P16; PROTEIN P53;

ADULT; ARTICLE; CANCER STAGING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; UTERINE CERVICITIS; UTERINE CERVIX CARCINOMA IN SITU;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; PAPILLOMAVIRUS INFECTIONS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; TURKEY; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 78751534278     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Jemal A., Thomas A., Murray T., Thun M.: "Cancer statistics 2002". CA Cancer J. Clin., 2002, 52, 23.
2. Lorincz A.T., Reid R., Jenson A.B., Greenberg M.D., Lancaster W., Kurman R.J.: "Human papilloma virus infection of the cervix: relative risk associations of 15 common anogenital types". Obstet. Gynecol., 1992, 79, 328.
3. Bauer H.M., Ting Y., Greer CE., Chambers J.C., Tashiro C.J., Chimera J. et al.: "Genital human papilloma virus infection in female university students as determined by a PCR- based method". JAMA, 1991, 265, 472.
4. Muñoz N., Bosch F.X., De Sanjose S., Herrero R., Castellsagué X., Shah K.V. et al.: "Epidemiologic classification of human papilloma virus types associated with cervical cancer". N. Engl. J. Med., 2003, 548, 518.
5. Bergeron C., Barrasso R., Beaudenon S., Flamant P., Croissant O., Orth G.: "Human papilloma viruses associated with cervical intraepithelial neoplasia: Great diversity and distinct distribution in low and high grade lesions". Am. J. Surg. Pathol., 1992, 16, 641.
6. Koutsky L.: "Epidemiology of genital human papillomavirus infection". Am. J. Med., 1997, 102, 3.
7. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M.: "The E6 oncoprotein encoded by human papilloma virus types 16 and 18 promotes the degradation of p53". Cell., 1990, 63, 1129.
8. Bragança J.F., Sarian L.O., Pitta D.R., Maito A.B., Vassallo J., Pignataro F. et al: "Expression of p16INK4a and cervical infection with high-risk human papillomavirus are not related to p53 activity in cervical intraepithelial neoplasia". Int. J. Gynecol. Cancer, 2008, 18, 1060.
9. Munger K., Phelps W.C., Bubb V., Howley P.M., Schlegel R.: "The E6 and E7 genes of the human papilloma virus type 16 together are necessary and sufficient for transformation of primary human keratinocytes". J. Virol., 1989, 63, 4417.
10. Nieh S., Chen S.F., Chu T.Y., Lai H.C., Lin Y.S., Fu E. et al.: "Is p16(INK4A) expression more useful than human papilloma virus test to determine the outcome of atypical squamous cells of undetermined significance- categorized Pap smear? A comparative analysis using abnormal cervical smears with follow- up biopsies". Gynecol. Oncol., 2005, 97, 35.
11. Kanao H., Enomoto T., Ueda Y., Fujita M., Nakashima R., Ueno Y et al.: "Correlation between p14(ARF)/ p16(INK4A) expression and HPV infection in uterine cervical cancer". Cancer Lett., 2004, 213, 31.
12. O'Neill C.J., McCluggage W.G.: "P16 expression in the female genital tract and its value in diagnosis". Adv. Anat. Pathol., 2006, 13, 8.
13. Lin Z.H., Shen X.H., Jin Z., Kim Y., Lee E., Kim H. et al.: "Human papilloma virus genotyping by oligonucleotide microarray and p 16 expression in uterine cervical intraepithelial neoplasm and in invasive carcinoma in Korean women". Pathol. Int., 2005, 55, 491.
14. Wang J.L., Zheng B.Y, Li X.D., Angström T., Lindström M.S., Wallin K.L.: "Predictive significance of the alterations of p16INK4a, p14ARF, p53 and proliferating cell nuclear antigen expression in the progression of cervical cancer". Clin. Cancer Res., 2004, 10, 2407.
15. O'Neill C.J., McBride H.A., Connolly L.E., McCluggage W.G.: "Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential". Histopathology, 2007, 50, 851.
16. INK4a expression is related to grade of CIN and high-risk human papillomavirus but does not predict virus clearance after conization or disease outcome". Int. J. Gynecol. Pathol., 2004, 23, 354.
17. INK4a immunostaining in cytological and histological specimens from the uterine cervix: A systematic review and meta-analysis". Cancer Treat. Reviews, 2009, 35, 210.
18. Dimitrakakis C., Kymionis G., Diakomanolis E., Papaspyrou I., Rodolakis A., Arzimanoglou I. et al.: "The possible role of p53 and bel- 2 expression in cervical carcinomas and their premalignant lesions". Gynecol. Oncol., 2000, 77, 129.
19. Huang L.W., Chou Y.Y., Chao S.L., Chen T.J., Lee T.T.: "P53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome". Gynecol. Oncol., 2001, 83, 348.